Eloxx Pharmaceuticals (ELOX) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $59.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | IBIO |
|---|---|---|
| Share price | $15.18 | $0.92 |
| Market cap | $61.27M | $59.16M |
| 1-day change | +2.02% | -8.91% |
| YTD return | — | -52.33% |
| 1-year return | — | +5.75% |
| 5-year return | — | -99.80% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $3.82 |
| 52-week low | $8.20 | $0.78 |
| Distance from 52-week high | -35.13% | -75.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +151.98% | +518.48% |
| Average volume | 46.44K | 727.93K |
| Shares outstanding | 4.04M | 64.31M |
| Employees | 10 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ELOX vs IBIO FAQ
Which is bigger, Eloxx Pharmaceuticals or iBio?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $59.16M for iBio (IBIO).
Are Eloxx Pharmaceuticals and iBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eloxx Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for iBio.